The Isomorphic Labs Drug Design Engine unlocks a new frontier beyond AlphaFold
andsoitis
60 points
6 comments
July 17, 2026
Related Discussions
Found 5 related stories in 393.6ms across 14,015 title embeddings via pgvector HNSW
- Open Design: Use Your Coding Agent as a Design Engine steveharing1 · 197 pts · May 02, 2026 · 53% similar
- Using AI to improve a challenging reaction in medicinal chemistry ilreb · 52 pts · June 17, 2026 · 53% similar
- Our Approach to Bioresilience: Isomorphic Labs and Google DeepMind bookofjoe · 76 pts · July 18, 2026 · 52% similar
- AlphaEvolve: Gemini-powered coding agent scaling impact across fields berlianta · 274 pts · May 07, 2026 · 51% similar
- Rewrites.bio: 60x speedup in Genomics QC and AI rewrite principles for Science emiller88 · 15 pts · April 02, 2026 · 51% similar
Discussion Highlights (5 comments)
ashwon13
Would like more details technically on their approach. Is it a neuro-symbolic approach, do they do something beyond just scaling, or some other architecture breakthrough, but alas drug discovery must remain proprietary. Thank gods for capitalism!
bonsai_spool
This is from February 2026 and notably there’s no way for the public to try out the model, nor is it published in a peer-reviewed journal
tusimi
"In November 2024, preliminary results of CASP16 showed AlphaFold 3-based models did not significantly outperform older methods for predicting protein-ligand interactions. The top performing models in the CASP16 Pose Prediction for Pharma Targets section were ClusPro[13] and CoDock[14] utilizing AlphaFold 2 based predictions, human visual inspection, and manual adjustments.[15] In April 2025 Isomorphic Labs raised $600 Million in its first ever external funding round, led by Thrive Capital.[16][17]" https://en.wikipedia.org/wiki/Isomorphic_Labs
navvyeanand
This is old news.
puttycat
What technical advancement made this possible? The text is vague about this.